Edition:
United States

Humanwell Healthcare Group Co Ltd (600079.SS)

600079.SS on Shanghai Stock Exchange

18.23CNY
20 Sep 2017
Change (% chg)

¥0.00 (+0.00%)
Prev Close
¥18.23
Open
¥18.25
Day's High
¥18.27
Day's Low
¥18.18
Volume
4,716,257
Avg. Vol
10,107,838
52-wk High
¥21.68
52-wk Low
¥17.83

Chart for

About

Humanwell Healthcare (Group) Co., Ltd is a China-based company principally engaged in research and development, manufacture and distribution of medical and pharmaceutical products. The Company’s products are categorized into chemical drugs, chemical raw material medicines, traditional Chinese medicines, biological medicines and... (more)

Overall

Beta: 0.79
Market Cap(Mil.): ¥23,444.67
Shares Outstanding(Mil.): 1,286.05
Dividend: 0.11
Yield (%): 0.60

Financials

  Industry Sector
P/E (TTM): -- 31.91 16.25
EPS (TTM): -- -- --
ROI: -- 15.14 14.87
ROE: -- 16.37 13.89

BRIEF- Humanwell Healthcare Group unit sets up U.S. joint stock company for asset acquisition

* Says its unit Humanwell Healthcare USA,LLC set up U.S. joint stock company AGIC-HUMANWELL BLUE RIDGE (US) LIMITED

Sep 15 2017

BRIEF-Humanwell Healthcare Group unit receives GMP certificate

* Says its pharma unit received goods manufacture practice (GMP) certificate from Hubei Food and Drug Administration on Jan. 2

Sep 12 2017

BRIEF-Humanwell Healthcare Group issues 2017 1st tranche short-term financing notes worth 1 bln yuan

* Says it completed issuance of 2017 1st tranche short-term financing notes worth 1 billion yuan

Sep 07 2017

REFILE-BRIEF-Humanwell Healthcare to issue medium-term notes, sell bio-pharma unit

* Says it plans to issue up to 2.0 billion yuan ($303.19 million) medium-term notes

Aug 29 2017

BRIEF-Humanwell Healthcare Group issues 2017 3rd tranche super short-term financing notes worth 1.2 bln yuan

* Says it issued 2017 3rd tranche super short-term financing notes worth 1.2 billion yuan with a term of 270 days and interest rate of 4.6 percent

Aug 08 2017

BRIEF- Humanwell Healthcare Group sells 80 pct stake in unit to CSL BEHRING ASIA PACIFIC for $351.8 mln

* Says it sold 80 percent stake in a wholly owned biological product unit to CSL BEHRING ASIA PACIFIC LTD for $351.8 million

Aug 04 2017

BRIEF-Humanwell Healthcare Group unit receives GMP certificate

* Says its Hubei-based unit received a good manufacturing practice (GMP) certificate from Hubei Food and Drug Administration for active pharmaceutical ingredients

Jul 31 2017

BRIEF-Humanwell Healthcare gets approval to issue 2 bln yuan worth of commercial paper

* Says it gets approval to issue 2.0 billion yuan ($297.36 million) commercial paper

Jul 31 2017

BRIEF-Humanwell Healthcare Group gets nod for clinic trial

* Says it gets China Food and Drug Administration's approval for its recombinant human mouse chimeric anti human -EGFR monoclonal antibody injection' clinic trial

Jul 20 2017

BRIEF-Humanwell Healthcare's controlling shareholder to buy shares worth 250-500 mln yuan within 6 months

* Says controlling shareholder plans to buy 250-500 million yuan ($36.62-$73.24 million) worth of company shares within six months

Jun 27 2017

Earnings vs. Estimates